Press Releases

09.23.2016

Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation

09.22.2016

Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend

09.20.2016

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

09.16.2016

Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade® (infliximab)

09.16.2016

Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe

09.15.2016

OncoImmune Announces Option and License Agreement with Pfizer Inc.

09.15.2016

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes

09.14.2016

FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer’s Smoking Cessation Therapy, CHANTIX® (varenicline)

09.13.2016

Pfizer Launches New “Moodivator” App to Help Support, Encourage and Motivate People with Depression

09.12.2016

Circle Pharma enters into an agreement with Pfizer to build screening library of macrocyclic peptides

09.08.2016

AnTolRx, Inc. Announces Series A Equity Funding from Pfizer, JDRF and Orion Equity Partners, LLC to Develop Targeted Nanoparticle Tolerance Therapeutics

09.07.2016

Pfizer Appoints Chief Scientific Officer for Neuroscience Research